Mesoblast (NASDAQ:MESO) Lowered to Sell at StockNews.com

Mesoblast (NASDAQ:MESO - Get Free Report) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a report issued on Tuesday.

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Friday, January 12th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $13.67.

Mesoblast Trading Up 8.4 %

MESO stock traded up $0.51 during trading on Tuesday, reaching $6.59. 3,376,519 shares of the stock were exchanged, compared to its average volume of 2,100,008. The business has a 50 day moving average price of $2.41 and a 200-day moving average price of $2.34. The firm has a market capitalization of $669.08 million, a price-to-earnings ratio of -5.88 and a beta of 3.59. Mesoblast has a 1 year low of $1.61 and a 1 year high of $10.24.

Institutional Investors Weigh In On Mesoblast

Several institutional investors have recently bought and sold shares of MESO. Envestnet Asset Management Inc. acquired a new position in Mesoblast in the third quarter worth approximately $33,000. EWA LLC bought a new position in Mesoblast in the first quarter valued at about $40,000. Prosperity Wealth Management Inc. bought a new position in Mesoblast during the third quarter worth about $79,000. Vident Investment Advisory LLC boosted its holdings in Mesoblast by 12.8% during the fourth quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company's stock worth $82,000 after buying an additional 3,191 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Mesoblast in the 4th quarter valued at approximately $85,000. Institutional investors and hedge funds own 1.43% of the company's stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.